Idelalisib

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Idelalisib
Idelalisib.svg
Clinical data
Pronunciation /ˈdɛləlɪˌsɪb/
eye-DEL-ə-li-sib
Trade names Zydelig
AHFS/Drugs.com zydelig
Pregnancy
category
  • US: D (Evidence of risk)
Routes of
administration
Oral (tablets)
ATC code
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding >84%[2]
Metabolism Aldehyde oxidase (~70%), CYP3A4 (~30%);[1] UGT1A4 (minor)
Metabolites GS-563117 (inactive in vitro)
Onset of action Tmax = 1.5 hours
Biological half-life 8.2 hours
Excretion Feces (78%), urine (14%)
Identifiers
Synonyms GS-1101, CAL-101
CAS Number
PubChem CID
DrugBank
ChemSpider
KEGG
ChEBI
ChEMBL
ECHA InfoCard 100.235.089
Chemical and physical data
Formula C22H18FN7O
Molar mass 415.42 g/mol
3D model (Jmol)

Idelalisib (trade name Zydelig zye-DEL-ig,[2] codenamed GS-1101 or CAL-101) is a drug used for the treatment of certain hematological malignancies. The substance acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase.[3][4]

Medical uses[edit]

Idelalisib is a second-line drug for patients whose chronic lymphocytic leukemia (CLL) has relapsed. Used in combination with rituximab,[5] idelalisib is to be used in patients for whom rituximab alone would be considered appropriate therapy due to other existing medical conditions.[5] It appears to be very effective and leads to rapid resolution of lymphadenopathy and splenomegaly. However, the lymphocyte counts takes longer to decrease to normal levels with idelalisib. Idelalisib is effective in patients who have a p53 mutation, which otherwise tends to impart a poor prognosis in CLL patients. This is important as even the first line chemotherapy regimens, such as those incorporating fludarabine are ineffective in patients with p53 mutation.

It is also approved for the treatment of follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL), both in patients who have received at least two prior systemic therapies.[2]

Clinical trials[edit]

It was also being studied in clinical trials for first-line treatment in high-risk CLL patients, who are otherwise unable to tolerate aggressive chemotherapy due to their medical history or age, but these trials were terminated due to adverse effects.[6]

Adverse effects[edit]

Clinical symptoms include diarrhea, fever, fatigue, nausea, cough, pneumonia, abdominal pain, chills and rash. Laboratory abnormalities may include: neutropenia, hypertriglyceridemia, hyperglycemia and elevated levels of liver enzymes. Idelalisib's safety and effectiveness to treat relapsed FL and relapsed SLL were established in a clinical trial with 123 participants with slow-growing (indolent) non-Hodgkin lymphomas. All participants were treated with idelalisib and were evaluated for complete or partial disappearance of their cancer after treatment (objective response rate, or ORR). Results showed 54% of participants with relapsed FL and 58% of participants with SLL experienced ORR.[7]

The U.S. label for idelalisib has a boxed warning describing toxicities that can be serious and fatal, including liver toxicity, severe diarrhea, colon inflammation, lung tissue inflammation (pneumonitis) and intestinal perforation, and the manufacturer was required to put in place a Risk Evaluation and Mitigation Strategy (REMS) under which the risk of toxicities would be managed.[8]

In March 2016, as reports were made from three ongoing clinical trials of serious adverse events and deaths, mostly due to infections, the European Medicines Agency opened a review of the drug and its risks.[9] On March 21, 2016 Gilead Sciences (the manufacturer of idelalisib) alerted healthcare providers about decreased overall survival and increased risk of serious infections in patients with CLL and indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib.[10] The company also disclosed that it stopped six clinical trials in patients with CLL, SLL and iNHL due to an increased rate of adverse events, including deaths.[11]

Pharmacology[edit]

Mechanism of action[edit]

PI3Kδ kinase is expressed in normal and malignant B-cells. By inhibiting it, idelalisib induces apoptosis and prevents proliferation in cell lines derived from malignant B-cells and in primary tumor cells. It also inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5 signaling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow.[2]

Binding profile[edit]

Idelalisib is a competitive inhibitor of the ATP binding site of the PI3Kδ catalytic domain. Its in vitro potency and selectivity relative to the other Class I PI3K isoforms is the following:[12]

PI3K isoform IC50, nM IC50-based PI3Kδ-fold selectivity
PI3Kα 8,600 453
PI3Kβ 4,000 211
PI3Kγ 2,100 110
PI3Kδ 19 1

History[edit]

Regulatory[edit]

In July 2014, the FDA and EMA granted idelalisib approval to treat different types of leukemia.[7][13] The FDA is also granted approval for idelalisib to treat patients with relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic lymphoma. Idelalisib is intended to be used in patients who have received at least two prior systemic therapies.

References[edit]

  1. ^ "Clinical Pharmacology and Biopharmaceutics Review: Zydelig (idelalisib)" (PDF). U.S. Food and Drug Administration. p. 6. Retrieved 15 April 2016. 
  2. ^ a b c d "ZYDELIG (idelalisib) Tablets, for Oral Use. U.S. Full Prescribing Information" (PDF). Gilead Sciences, Inc. Retrieved 15 April 2016. 
  3. ^ H. Spreitzer (13 May 2013). "Neue Wirkstoffe – Ibrutinib und Idelalisib". Österreichische Apothekerzeitung (in German) (10/2013): 34. 
  4. ^ Wu, M.; Akinleye, A.; Zhu, X. (2013). "Novel agents for chronic lymphocytic leukemia". Journal of Hematology & Oncology. 6: 36. PMC 3659027Freely accessible. PMID 23680477. doi:10.1186/1756-8722-6-36. 
  5. ^ a b Furman, Richard R.; Sharman, Jeff P.; Coutre, Steven E.; Cheson, Bruce D.; Pagel, John M.; Hillmen, Peter; Barrientos, Jacqueline C.; Zelenetz, Andrew D.; Kipps, Thomas J.; Flinn, Ian; Ghia, Paolo; Eradat, Herbert; Ervin, Thomas; Lamanna, Nicole; Coiffier, Bertrand; Pettitt, Andrew R.; Ma, Shuo; Stilgenbauer, Stephan; Cramer, Paula; Aiello, Maria; Johnson, Dave M.; Miller, Langdon L.; Li, Daniel; Jahn, Thomas M.; Dansey, Roger D.; Hallek, Michael; O'Brien, Susan M. (2014). "Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia". New England Journal of Medicine. 370: 997–1007. PMC 4161365Freely accessible. PMID 24450857. doi:10.1056/NEJMoa1315226. 
  6. ^ Therapy Focus - TG Could Benefit From Zydelig Setback. March 2016
  7. ^ a b "FDA approves Zydelig for three types of blood cancers". Food and Drug Administration. July 23, 2014. 
  8. ^ "Press Announcements — FDA approves Zydelig for three types of blood cancers". www.fda.gov. Retrieved 2016-03-14. 
  9. ^ "European Medicines Agency — News and Events — EMA reviews cancer medicine Zydelig". www.ema.europa.eu. Retrieved 2016-03-14. 
  10. ^ "Important Drug Warning: Decreased Overall Survival and Increased Risk of Serious Infections in Patients Receiving ZYDELIG (idelalisib)" (PDF). Gilead Sciences, Inc. March 21, 2016. Retrieved 19 April 2016. 
  11. ^ "Drug Safety and Availability — FDA Alerts Healthcare Professionals About Clinical Trials with Zydelig (idelalisib) in Combination with Other Cancer Medicines". FDA Center for Drug Evaluation and Research. Retrieved 19 April 2016. 
  12. ^ "Committee for Medicinal Products for Human Use Assessment Report: Zydelig (idelalisib)" (PDF). European Medicines Agency. p. 17. Retrieved 19 April 2016. 
  13. ^ "European Medicines Agency recommends approval of two new treatment options for rare cancers". European Medicines Agency. July 25, 2014. 

External links[edit]